Literature DB >> 25487240

Use of High-Flow Continuous Renal Replacement Therapy with Citrate Anticoagulation to Control Intracranial Pressure by Maintaining Hypernatremia in a Patient with Acute Brain Injury and Renal Failure.

Joshua E Medow1, Shalin R Sanghvi2, R Michael Hofmann2.   

Abstract

Traumatic brain injury and intracranial hypertension often require treatment to optimize patient outcome. There are a variety of complex medical conditions that can preclude standard approaches to the treatment of intracranial hypertension. We describe a case where a novel approach using continuous dialysis with trisodium citrate was used to optimize the outcome of a young male with acute renal failure and acute respiratory distress syndrome in the setting of acute traumatic brain injury.
© 2015 Marshfield Clinic.

Entities:  

Keywords:  CRRT; CVVH; Dialysis; Intracranial pressure; Renal failure

Mesh:

Substances:

Year:  2014        PMID: 25487240      PMCID: PMC4504660          DOI: 10.3121/cmr.2014.1238

Source DB:  PubMed          Journal:  Clin Med Res        ISSN: 1539-4182


  15 in total

Review 1.  Renal replacement therapy in the patient with acute brain injury.

Authors:  A Davenport
Journal:  Am J Kidney Dis       Date:  2001-03       Impact factor: 8.860

2.  Use of hypertonic saline in the treatment of severe refractory posttraumatic intracranial hypertension in pediatric traumatic brain injury.

Authors:  S Khanna; D Davis; B Peterson; B Fisher; H Tung; J O'Quigley; R Deutsch
Journal:  Crit Care Med       Date:  2000-04       Impact factor: 7.598

3.  Introducing hypertonic saline for cerebral edema: an academic center experience.

Authors:  Lisa L Larive; Denise H Rhoney; Dennis Parker; William M Coplin; J Ricardo Carhuapoma
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

4.  Acute renal failure following massive mannitol infusion.

Authors:  Angel J Pérez-Pérez; Beatriz Pazos; José Sobrado; Luis Gonzalez; Argimiro Gándara
Journal:  Am J Nephrol       Date:  2002 Sep-Dec       Impact factor: 3.754

5.  Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial.

Authors:  C Ronco; R Bellomo; P Homel; A Brendolan; M Dan; P Piccinni; G La Greca
Journal:  Lancet       Date:  2000-07-01       Impact factor: 79.321

6.  A novel method for regional citrate anticoagulation in continuous venovenous hemofiltration (CVVHF).

Authors:  R Michael Hofmann; Christine Maloney; David M Ward; Bryan N Becker
Journal:  Ren Fail       Date:  2002-05       Impact factor: 2.606

7.  Citrate anticoagulation and adverse events.

Authors:  J De Vos; R Hombrouckx
Journal:  EDTNA ERCA J       Date:  2003 Jul-Sep

8.  The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure.

Authors:  Nicholas Murphy; Georg Auzinger; William Bernel; Julia Wendon
Journal:  Hepatology       Date:  2004-02       Impact factor: 17.425

9.  Intensity of renal support in critically ill patients with acute kidney injury.

Authors:  Paul M Palevsky; Jane Hongyuan Zhang; Theresa Z O'Connor; Glenn M Chertow; Susan T Crowley; Devasmita Choudhury; Kevin Finkel; John A Kellum; Emil Paganini; Roland M H Schein; Mark W Smith; Kathleen M Swanson; B Taylor Thompson; Anitha Vijayan; Suzanne Watnick; Robert A Star; Peter Peduzzi
Journal:  N Engl J Med       Date:  2008-05-20       Impact factor: 91.245

10.  Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study.

Authors:  Mehran Monchi; Denis Berghmans; Didier Ledoux; Jean-Luc Canivet; Bernard Dubois; Pierre Damas
Journal:  Intensive Care Med       Date:  2003-11-05       Impact factor: 17.440

View more
  1 in total

Review 1.  Therapeutic hypernatremia management during continuous renal replacement therapy with elevated intracranial pressures and respiratory failure.

Authors:  Tibor Fülöp; Lajos Zsom; Rafael D Rodríguez; Jorge O Chabrier-Rosello; Mehrdad Hamrahian; Christian A Koch
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.